ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~83ffff̙̙3f3fff3f3f33333f33&Pursuant to Section 13 or 15d o&PRINCETON NJ February 13 2020 A l  U  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!PRINCETON NJ February 13 2020 AU } } 6       Advaxis, Inc. 8-K 02/13/2020NFPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 [ ]/'Written communications pursuant to Rule 5 -425 under the Securities Act (17 CFR 230.425)   [ ]3 +Soliciting material pursuant to Rule 14a-12 2 *under the Exchange Act (17 CFR 240.14a-12)   [ ]0(Pre-commencement communications pursuant/'to Rule 14d-2(b) under the Exchange Act(17 CFR 240.14d-2(b)) [ ]0(Pre-commencement communications pursuant/'to Rule 13e-4(c) under the Exchange Act(17 CFR 240.13e-4(c))$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8&dXL@[R:sK=PF0*8X> @ l  #  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!Pursuant to Section 13 or 15d oU } $ } $} 6 #      Advaxis, Inc. 8-K 02/13/2020kcPRINCETON, N.J. February 13, 2020 Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology comp ?0(Median overall survival (95% CI) of 33.7  - %months (15.4-NR) for patients treated  3 +with ADXS-PSA in combination with KEYTRUDA?   (n=37)  ?0 (Median overall survival (95% CI) of 16.0  1 )months (6.4-34.6) for patients with priordocetaxel (n=20) ?0(Median overall survival (95% CI) of 16.4/'months (4.0-NR) for patients with prior0(visceral metastasis (n=11; 10 of who hadprior docetaxel) ?2*72.4% (21/29) of evaluable patients showedstable disease ?0(38% of patients had PSA declines and 27%,$had >= 30% PSA decline from baseline ?5-The combination of ADXS-PSA and pembrolizumab3+appeared safe and tolerable in this heavily,$pretreated, unselected population of-%patients with MSI-High-negative mCRPC ?-%Treatment-related adverse events were3+mostly Grade 1-2, with no additive toxicity)!observed with combination therapyD lG;/#>zFb.`w/M !"$ ____________________________1!)Created by Morningstar Document Research.0"(http://documentresearch.morningstar.com/ (=PF0*8X> @""!!  Root Entry FBook  W